“We have been evaluating opportunities in the Cannabis space for several years and Piauhy’s scientific approach to medical cannabis aligned well with our investment philosophy. We are impressed with the scientific endeavors of the company, its capital efficiency and the timing of the European medical cannabis market. Our investment, combined with the expertise of the company’s team, led by its CEO,
The company was created in 2018 by
In 2020, Infarmed, the
This round proceeds allow Piauhy to advance with the facility construction, initiate the R&D protocols and foster its commercial efforts.
“We are very happy with this important milestone and delighted that Migration’s focus on disruptive innovations matched our ambitions. We are at the crossroads of biotech, neurosciences and medical cannabis”, says
An European based science driven medical cannabis company, committed to producing high quality, personalized medicine – Positioned at the crossroad of biotechnology, neuroscience, and medicinal cannabis.
View original content to download multimedia:http://www.prnewswire.com/news-releases/piauhy-labs-announces-its-latest-funding-round-led-by-migration-capital-301282974.html